Get a glimpse into our company and investor data—powered by the PitchBook Platform
PhIII Crohn's drug
Asset Purch.LATEST DEAL TYPE
A right of an oral antisense DNA oligonucleotide drug. The asset comprises of phase III trial drug producing assets targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease (CD) and other indications.